Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Industry News

FDA Approves New AGGRASTAT® Product Format

September 01, 2016

News Industry News

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

October 20, 2015

News Industry News

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

September 10, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Industry News

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

July 07, 2014

News Industry News

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

April 16, 2013

News Industry News

Case Report: Use of OrbusNeich’s Genous™ Stent with Bivalirudin for Acute Coronary Syndrome Patients at Risk for Bleeding Due to Hematological Cancer

December 16, 2012

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Industry News

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

October 23, 2012

News Industry News

OrbusNeich's Genous™ Stent Is Safe and Effective in Patients Who Discontinue Dual Antiplatelet Therapy (DAPT) Within 15 Days of Stent Placement

June 21, 2012

News Industry News

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

July 20, 2011

News Industry News

2011 ACCF/AHA Guidelines Incorporate New Recommendation for Platelet Reactivity Testing

March 31, 2011

News Industry News

Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction

March 29, 2011

Advertisement

FDA Approves New AGGRASTAT® Product Format

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

Case Report: Use of OrbusNeich’s Genous™ Stent with Bivalirudin for Acute Coronary Syndrome Patients at Risk for Bleeding Due to Hematological Cancer

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

OrbusNeich's Genous™ Stent Is Safe and Effective in Patients Who Discontinue Dual Antiplatelet Therapy (DAPT) Within 15 Days of Stent Placement

FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US

2011 ACCF/AHA Guidelines Incorporate New Recommendation for Platelet Reactivity Testing

Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content